Three-dimensional printing (3DP) has the potential to cause a paradigm shift in the manufacture of pharmaceuticals, enabling personalised medicines to be produced on-demand. To facilitate integration into healthcare, non-destructive characterisation techniques are required to ensure final product quality. Here, the use of process analytical technologies (PAT), including near infrared spectroscopy (NIR) and Raman confocal microscopy, were evaluated on paracetamol-loaded 3D printed cylindrical tablets composed of an acrylic polymer (Eudragit L100-55). Using a portable NIR spectrometer, a calibration model was developed, which predicted successfully drug concentration across the range of 4-40% w/w. The model demonstrated excellent linearity (R 2 = 0.996) and accuracy (RMSEP = 0.63%) and results were confirmed with conventional HPLC analysis. The model maintained high accuracy for tablets of a different geometry (torus shapes), a different formulation type (oral films) and when the polymer was changed from acrylic to cellulosic (hypromellose, HPMC). Raman confocal microscopy showed a homogenous drug distribution, with paracetamol predominantly present in the amorphous form as a solid dispersion. Overall, this article is the first to report the use of a rapid 'point-and-shoot' approach as a non-destructive quality control method, supporting the integration of 3DP for medicine production into clinical practice.
Introduction
Three-dimensional printing (3DP) has been forecast to revolutionise the pharmaceutical sector, moving away from a 'one-size-fits-all' treatment approach towards personalisation. Indeed, 3DP technology allows medicines to be tailored to the individual needs of each patient, for example, by modifying the dosage, shape, size and release characteristics, as well as via production of multi-drug combinations Awad et al., 2018a,b; Ghosh et al., 2018; Sadia et al., 2018b; Smith et al., 2018; Trenfield et al., 2018; Verstraete et al., 2018; Zema et al., 2017) .
To date, five main 3DP technologies have been researched within pharmaceuticals; binder jet printing (Wang et al., 2006; Yu et al., 2009a,b) , fused deposition modelling (FDM) (Gioumouxouzis et al., 2018; Goyanes et al., 2014 Goyanes et al., , 2015a Goyanes et al., , 2018 Goyanes et al., , 2017a Goyanes et al., , 2016b Maroni et al., 2017; Melocchi et al., 2016) , semi-solid extrusion (Khaled et al., 2018; Khaled et al., 2015a,b) , selective laser sintering (SLS) (Fina et al., 2018a (Fina et al., ,b, 2017 and stereolithography (SLA) (Goyanes et al., 2016a; Martinez et al., 2017; Muwaffak et al., 2017; Wang et al., 2016) . All of the 3DP technologies follow the 3 D's of 3D printing ; a) design: computer aided design software is used to create the dosage form; b) develop: the selected drug(s) and polymer(s) are blended and loaded into the 3D printer and c) dispense: the 3D dosage form is fabricated, in a layer by layer manner, to meet the design requirements.
Due to the versatile, compact and user-friendly nature of these 3DP processes, it is likely that this technology could initiate a new era of digital pharmacy; with medicine design and production occurring directly at the point of care, such as within hospital and community pharmacies Lim et al., 2018) . A proposed treatment pathway could involve clinical data being sent to a clinician for review. A medicine could then be designed to meet the patient's T therapeutic requirements (in the form of a digital prescription) and sent to a local 3D printer for dispensing on-demand Awad et al., 2018a; Trenfield et al., 2018) .
Despite the many well-documented benefits that 3DP could provide, adoption of this technology for personalised medicine production has not yet occurred. Indeed, the relative lack of clinical experience, in conjunction with the unique features of 3DP compared with more established manufacturing processes, pose a number of challenges before it can be widely integrated (Norman et al., 2017) . Most notably, these relate to the matters of quality control (QC) and safety; such as, how dose verification and drug distribution within the 3D printed tablets can be ensured .
Conventionally, solid oral dosage forms require content uniformity and dose verification testing, typically by using high performance liquid chromatography (HPLC) or UV spectroscopy assays. Such tests are performed on samples from a large batch, which is clearly impossible for a manufacturing process capable of fabricating single tablets. In addition, the tests are destructive, expensive and require highly skilled operators and thus would be impractical within a clinical setting. The best solution would involve utilising a novel, non-destructive tablet characterisation method to permit real-time batch release at the clinic . Process analytical technologies (PAT), such as spectroscopic tools including near infrared (NIR) and Raman spectroscopy, have been previously shown to be capable of monitoring tablet critical quality attributes (CQAs), namely drug content (Meza et al., 2006; Wartewig and Neubert, 2005) , hardness , drug distribution (Eksi-Kocak et al., 2018; Jérez Rozo et al., 2011) and solid state characteristics (Netchacovitch et al., 2017) . In particular, NIR spectroscopy is favourable due to its rapid speed of analysis (seconds), non-invasive and non-destructive nature, ability to analyse solid samples and low cost (Luypaert et al., 2007; Teixeira et al., 2018) .
Previous studies have evaluated the use of PAT technologies for drug quantification of two-dimensional (2D) inkjet printed formulations (Edinger et al., 2017; Vakili et al., 2016 Vakili et al., , 2017 . In contrast, to date, no such research has been performed around using a simple, 'point-and-shoot' approach to quantify accurately the dosage within 3D printed drug products. A key benefit of 3DP lies in its ability to flexibly change the dosage form geometry, formulation type or excipients depending on the patient's preferences or therapeutic requirements. Indeed, several papers have reported the differing effects of dosage form shape or structure on both drug release (Fina et al., 2018a; Goyanes et al., 2015c; Martinez et al., 2018; Sadia et al., 2018a; Wang et al., 2016; Yang et al., 2018) and patient acceptability (Goyanes et al., 2017b) . As such, a user-friendly and rapid technique that accurately measures dosage irrespective of the formulation design and composition would be highly advantageous.
Therefore, this study aimed to create a model that could predict paracetamol concentration in 3D printed tablets, herein termed printlets, fabricated using SLS. The applicability of the model to tablets of different geometries (cylindrical and torus shapes), as well as those composed of different excipients (acrylic and cellulosic polymers) and different formulation types (oral films) were evaluated. The printlets were also characterised using Raman confocal microscopy to observe drug distribution and solid state characteristics within the printlet structure.
Materials and methods
Paracetamol USP grade (Sigma-Aldrich, UK) was used as a model drug (MW 151.16 , aqueous solubility at 37°C: 21.80 g/L) (He et al., 2010) . Eudragit L100-55, which is a copolymer of methacrylic acid and ethyl acrylate (1:1 ratio) that dissolves at pH 5.5 and above, was donated by Evonik, UK. Hydroxypropyl methylcellulose (HPMC) Vivapharm E5 was acquired from JRS PHARMA, Germany. Candurin® Gold Sheen was purchased from Azelis, UK.
3D printing process
AutoCAD 2014 (Autodesk Inc., USA) was used to design the templates for the printlets: (cylindrical, 10 mm diameter × 3.6 mm height; torus-shaped, 10 mm diameter × 4 mm height; and oral films, 10 mm × 10 mm × 0.5 mm). Fig. 1 shows examples of each printlet design and image after printing. 3D models were exported as a stereolithography (.stl) file into the 3D printer Sintratec Central software Version 1.1.13.
For all formulations, 70 g of paracetamol and the required excipients were blended using a mortar and pestle (Table 1) . 3% w/w of Candurin® Gold Sheen was added to all the formulations to enhance energy absorption from the laser to allow printability. Powder mixtures were transferred to a desktop SLS printer (Sintratec Kit, AG, Brugg, Switzerland) in order to fabricate the printlets. Powder in the reservoir platform (150 mm × 150 mm × 150 mm) of the printer was transferred by a sled to a build platform (150 mm × 150 mm × 150 mm), creating a flat and homogeneously distributed layer of powder.
For all Eudragit L100-55 formulations, the chamber temperature was set to 90°C, indicating the temperature inside the printer; and the surface temperature was set to 110°C, indicating the surface temperature of the powder bed during printing. For HPMC E5 formulations, Paracetamol content (% w/w) these temperatures were set at 115°C and 135°C, respectively. The printing process started with the activation of a 2.3 W blue diode laser (445 nm; laser scanning speed 100 mm/s) to sinter the powder on to the build platform in a specified pattern based on the .stl file. After the first layer of the printlet had been created, the reservoir platform moved up, the build platform moved down, and the sled distributed a thin layer of powder on top of the powder bed. This process was repeated layer-bylayer until printing was complete. The printlets were then removed from the powder bed and the excess powder was brushed off. Three printlets were printed at the same time for each formulation.
Near infrared spectroscopy (NIR) data acquisition
NIR reflectance spectra were measured using a portable benchtop Labspec 5000 near infrared spectrometer (Analytical Spectral Devices, USA), equipped with three separate holographic diffraction gratings and three separate detectors; a 512-element silicon photo-diode array for wavelengths between 350-1000 nm, and two TE-cooled InGaAs for wavelengths between 1000-1800 nm and 1800-2500 nm. Spectra were collected using an immobilised lab grade 1 m fibre optic cable (fibre core size 200 μm), which interfaced with the NIR equipment (BIF200-Vis-NIR, Ocean Optics Inc., FL, USA). A Spectralon 99% reflective standard (Labsphere, North Sutton, UK) was used for instrument calibration prior to spectra acquisition. UV-visible-NIR spectra were collected across the 300-2500 nm wavelength region (2200 data points) totalling 64 scans, which were averaged.
Each printlet was analysed at six different points to avoid potential sampling errors and to reduce the variability caused by different surface effects. Standard printlets were scanned twice on the topside, twice on the underside and once on each side. Torus shaped printlets and oral films were scanned three times on the topside and three times on the underside. The final spectrum (used to calculate paracetamol content) was the average of the spectra recorded at the six positions.
Model development
Seven printlet concentrations (n = 3) were selected for calibration model development (4%, 8%, 16%, 24%, 28%, 36% and 40% w/w), and three concentrations (n = 3) were used for internal validation (12%, 20% and 32% w/w). Multivariate data analysis was performed using MATLAB software version R2017a (The MathWorks, CA, USA) with the PLS Toolbox version 8.6 (Eigenvector, CA, USA) for data preprocessing and modelling. Partial least squares (PLS) regression was performed on the datasets to build calibration models. The models were internally cross-validated using venetian blinds.
Validation of the NIR calibration model was performed according to International Conference on Harmonization (ICH) guidance Q2(R1) (ICH, 2005) , and other regulatory guidance from the European Medicines Agency (EMA) (EMA, 2014) and the Food and Drug Administration (FDA) (FDA, 2015) , by assessing model specificity, linearity (expressed as correlation coefficient, R 2 ), accuracy (expressed as the root mean square error of prediction; RMSEP), precision and intermediate precision (expressed as relative standard deviation; RSD). The predictive performance of the model was evaluated by scanning an external validation set of Eudragit L100-55 printlets at 12%, 20% and 32% w/w concentrations. To evaluate whether the model would work when changing printlet geometry and dosage form type, 3D printed torus shaped printlets and oral films were also scanned. Moreover, the predictive performance of the model in the presence of other excipients was evaluated by changing the polymer to HPMC E5.
Determination of drug content
Following NIR analysis, each individual printlet was quantitatively analysed for drug content using high performance liquid chromatography (HPLC). Three individual printlets of each formulation were placed in separate volumetric flasks with deionised water (250 mL). For Eudragit L100-55-based printlets, 3 drops of 5 N NaOH were added to each flask to increase the pH to enable dissolution. Samples of solution were then filtered through 0.22 μm filters (Millipore Ltd., Ireland) and the concentration of drug determined with HPLC (Hewlett Packard 1050 Series HPLC system, Agilent Technologies, UK). The validated HPLC assay entailed injecting 20 μL samples for analysis using a mobile phase, consisting of methanol (15%) and water (85%), through an Ultra C8 5 μm column, 250 × 4.6 mm (Restek, USA) maintained at 40°C. The mobile phase flow rate was 1 mL min −1 and the eluent was screened at a wavelength of 247 nm.
Raman spectroscopy and mapping
Raman mapping was performed to evaluate the distribution of drug and polymer within the printlets. The underside surface and cross section of samples (40% w/w) were mounted and focused using a X50 objective on an InVia confocal Raman microscope (Renishaw, UK) equipped with a 300 mW 785 nm HPNIR Renishaw laser. Spectral arrays were acquired with ca. 4500 spectra recorded over a ca. 300 μm × 300 μm (X × Y) surface of the sample using a step size of 5 μm in X and Y. A 1200 line grating was used providing spectral resolution up to 1 cm −1 . Spectra were collected over the range of 1190-1695 nm, with a 2 s exposure time and 2 accumulations.
Processing was performed using Renishaw WiRE software v.3.4 using direct classical least-squares (DCLS) component matching to paracetamol (amorphous and crystalline, form I) and Eudragit L100-55 reference spectra to generate 2-dimensional false colour maps.
X-ray powder diffraction
X-ray powder diffraction patterns of printlets (ground to a fine powder), formulation blends and pure paracetamol were recorded using a Rigaku MiniFlex 600 (Rigaku, USA) with a Cu Kα X-ray source (λ = 1.5418 Å) and accompanying software Miniflex Guidance version 1.2.01. The intensity and voltage applied were 15 mA and 40 kV. The angular range of data acquisition was 3-40°2θ, with a step size of 0.02°a t a speed of 2°min −1 .
Results and discussion
To facilitate the integration of 3DP into pharmacy practice, the development of rapid, non-destructive quality control techniques that permit real time batch release are required. A relatively new 3DP technology to pharmaceuticals is SLS printing which, to date, has been used to manufacture a range of dosage forms, including immediate and controlled release tablets (Fina et al., 2017 (Fina et al., , 2018a , as well as fast disintegrating oro-dispersible tablets (Fina et al., 2018b) . In the present study, for the first time the manufacture of standard cylindrical and novel torus-shaped printlets, as well as 3D printed oral films, containing a high drug loading (up to 40% w/w) were successfully produced (Fig. 1) . Paracetamol and Eudragit L100-55 were selected as the model drug and excipient for calibration development.
Drug distribution and solid state analysis
To ensure paracetamol was homogenously distributed within the printlets, Raman confocal microscopy was used which is a non-destructive method commonly employed to evaluate drug distribution, as well as the amorphous and crystalline content, of pharmaceutical tablets and films (Goyanes et al., 2015d; Netchacovitch et al., 2017; Scoutaris et al., 2014) . Within this study, a 300 μm × 300 μm sized section on the external underside surface and internal cross section of a printlet (40% w/w) was scanned using a Raman microscope. At each point of the formulation mapped, reference paracetamol (amorphous and crystalline; form I) and Eudragit L100-55 spectra were inputted into the software and compared with the printlet spectra collected using DCLS.
Paracetamol was homogenously distributed across the internal structure and surface of the printlet ( Fig. 2A and 3A) . In particular, the underside surface of the printlet consisted of paracetamol that was mostly present in the amorphous phase ( Fig. 2A ; red areas). It was found that the distribution of the polymer (Eudragit L100-55) predominantly overlaps with amorphous paracetamol, suggesting that in these areas paracetamol was present as a solid dispersion (Fig. 2B) . Similar results have also been reported elsewhere (Fina et al., 2017) . There is special interest in delivering drugs as solid dispersions as a strategy to enhance drug dissolution and bioavailability, particularly for drugs with inherently low solubility (e.g. BCS Class II or IV compounds) (Capretto et al., 2017; Martínez et al., 2014) . As well as SLS, other thermal 3DP methods have shown the capability of formulating a variety of drugs as amorphous or semi-amorphous systems (Kollamaram et al., 2018; Sadia et al., 2016) . Within the SLS printing process, it is likely that the application of heat and laser results in complete drug melting to enable formation of a non-crystalline matrix. This process would differ based on the drug, excipients and printing parameters (e.g. laser scanning speed, chamber temperature) selected.
Areas of crystalline paracetamol form I (green areas) were also present ( Fig. 2A) . The areas of crystalline material were attributed to the presence of residual unsintered powder on the surface of the tablet that had not been effectively cleared away after printing. To confirm this, a cross section of the same printlet was taken and the internal structure was viewed using the Raman microscope. Fig. 3A and B show that paracetamol was entirely present in the amorphous phase, which was distributed amongst the Eudragit L100-55 matrix as a solid dispersion. This confirms that the amorphous material was not re-crystallising out of the matrix and is instead likely due to remaining unsintered powder on the surface. Excess powder remaining on the surface or trapped inside the pores of SLS printed objects has previously been reported (Bose et al., 2013; Williams et al., 2005) .
To verify the Raman microscopy findings, XRPD data were collected for both the powder blends and the standard printlets (Fig. 4) . For the 20% and 40% w/w drug-loaded powder blends, characteristic paracetamol form I peaks can be observed although these were not observed at the 4% concentration. It is likely that, while paracetamol would be present in the crystalline form at 4% w/w, it would be below the detection limit of XRPD analysis. For the printed formulations, the 20% w/w concentration showed complete conversion of paracetamol into the amorphous form, confirming that the drug was dispersed into the polymer matrix. At 40% w/w, it can be seen that the majority of paracetamol has been converted into the amorphous form (due to peak height reduction), although several crystalline paracetamol peaks can be observed. This is most likely attributed to the presence of residual unsintered powder on the surface of the printlet, which was observed in the aforementioned Raman maps (Figs. 2 and 3) . Fig. 2 . External underside surface of a printlet (40% w/w paracetamol) mapped using Raman confocal microscopy. Red areas = amorphous paracetamol (A), green areas = crystalline paracetamol (Form I), blue areas = Eudragit L100-55 (B). Fig. 3 . Internal cross section of a printlet (40% w/w paracetamol) mapped using Raman confocal microscopy. Red areas = amorphous paracetamol (A), blue areas = Eudragit L100-55 (B).
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Quantitative analysis using NIR
To create a reliable multivariate calibration model, the evaluation of different spectral pre-processing methods was required in order to extract the relevant chemical information. In this study, a total of ten PLS models were developed (Table 2) ; six different pre-treatments were applied to the spectra and for each, two different spectral ranges were evaluated; SR1: 1100-2360 nm and SR2: 1300-2100 nm. For each model, the correlation coefficient of the calibration curve (R 2 Cal) and the standard error of the calibration curve (RMSEC) were calculated in order to determine the predictive performance of the model. The correlation coefficient of the test printlets (R 2 Pred) and standard error of the test printlets (RMSEP) were then calculated for the validation set and the most suitable model was defined as the model with the lowest RMSEP value with high linearity (i.e. R 2 Pred as close to 1 as possible).
In this case, the model selected was model 10, which covered the 1300-2100 nm wavelength range with a 2nd derivative (Sativzky-Golay method: filter width of 41 with a 2nd polynomial (Savitzky and Golay, 1964) ) and mean-centering pre-processing technique. These pre-treatments are commonly used to improve the accuracy of quantification by enhancing spectral information, reducing baseline drift and reducing error caused by light scattering effects (Chalus et al., 2005 ). The calibration model developed covered a total of 30 samples (with 7 concentrations being selected for calibration and 3 for validation) over a paracetamol concentration range of 4-40% w/w. 
Specificity
For the model to be fit-for-purpose, it must have the ability to identify explicitly the analyte (i.e. paracetamol) in the presence of the other components (i.e. Eudragit L100-55 and the colourant). This was evaluated by comparing the loadings spectra of the 1st latent variable (LV1), which accounted for 88.8% of the variation in the data, to the Fig. 4 . X-ray powder diffraction patterns of pure paracetamol (form I), powder blends (4%, 20% and 40% w/w paracetamol) and printlets (4%, 20% and 40% w/w paracetamol). S.J. Trenfield et al. International Journal of Pharmaceutics 549 (2018) 283-292 reference component spectrum in the 2nd derivative ( Fig. 6A and C) . LV1 was found to model well-known paracetamol spectral features at 1625-1675 nm (Trafford et al., 1999) and 2000-2050 nm (highlighted by the red dashed lines on Fig. 6 ). LV1 was not found to be modelling the common spectral features of Eudragit L100-55 or Candurin Gold Sheen ( Fig. 6B and 6D ). This confirmed that the majority of the variation in the data was caused by the change in paracetamol concentration. Un-processed and pre-processed spectra of both the raw materials and the scanned printlets (4-40% w/w) have been provided in Supplementary files Figs. 1 and 2. Supplementary data associated with this article can be found, in the online version, at https://doi.org/10.1016/j.ijpharm.2018.08.002.
Accuracy
The accuracy of the calibration model can be expressed as the closeness in agreement between the reference HPLC and the predicted NIR values (Table 3) . ICH Q2 guidance recommends assessing accuracy using a minimum of nine determinations over a minimum of three concentration levels (ICH, 2005) . As such, standard printlets (n = 3) from three concentration levels (A: 12%, B: 20% and C: 32% w/w) were scanned. Table 3 shows the difference between the HPLC and NIR predicted paracetamol concentrations. Paired t-test results showed that there were no significant differences between the HPLC and NIR methods (p > 0.05) across all three concentrations, confirming that NIR is a suitable quantification method for standard printlets. Compared with HPLC, NIR predictions displayed a slightly higher SD, which was more evident at lower concentrations. This is likely due to minute differences in the surface effects of the printlets. However, this was not as high for the generally allowed limits of 85-115% required for content uniformity testing by the MHRA (MHRA, 2018). Accuracy was also confirmed by having a low error value (RMSEP of 0.63%) and low prediction bias of −0.26%, which were similar to findings in the literature (Trafford et al., 1999) (Fig. 5) .
One of the main benefits of 3D printing for personalised medicine is the ability to tailor solid dosage form shape and size, depending on the patient preference or therapeutic needs . Several studies have already shown that changing printlet geometry can alter the dose and drug release characteristics (Goyanes et al., 2015c; Martinez et al., 2018; Sadia et al., 2018a) . It is also well known that NIR absorbance can be affected by tablet surface effects (Jamrógiewicz, 2012; Saeed et al., 2009) and, as such, it was important to evaluate the performance of the developed PLS model when scanning printlets of different geometries.
To determine this, torus shaped printlets (12%, 20% and 32% w/w) and oral films with the same formulation composition as the standard shape were scanned at six different points on the formulation. Fig. 7A and B show that the model predicted the concentrations well, as the points fitted on the calibration curve. Torus shaped printlets displayed a slightly higher error compared to oral films (RMSEP values of 2.05% and 1.14%, respectively), which is likely due to the complex rounded surface structure of this shape, compared with the flat films. However, overall the model continued to be fit-for-purpose for use with differently shaped tablets of the same composition.
A further benefit of using 3DP for personalised medicine is the flexibility of changing excipients based on the intended drug release characteristics. Previous studies have highlighted the effects of different Fig. 7 . PLS models of NIR predicted vs. HPLC determined paracetamol content (% drug load; %DL) of A) film shaped printlets and B) torus shaped printlets. Grey points are calibration (7 concentrations), red points are the test sets (3 concentrations).
S.J. Trenfield et al. International Journal of Pharmaceutics 549 (2018) 283-292 polymer types (Ehtezazi et al., 2018; Fina et al., 2018a; Goyanes et al., 2015b; Kadry et al., 2018; Kempin et al., 2017; Zhang et al., 2017) and grades (Goyanes et al., 2017a) on drug dissolution. In the present study, the calibration model was developed using an acrylate-based polymer (Eudragit L100-55), however the ability for this model to be applied to another type of polymer was evaluated. In particular, an external test set of cylindrical printlets were printed that were composed of HPMC E5, an immediate release cellulosic polymer, and the predictive performance of the model was evaluated (Fig. 8) .
Despite the change in polymer, an excellent predictive performance was observed (high linearity; R 2 = 0.984, high accuracy; RMSEP = 1.36%; Fig. 8 ). Generally, changing the formulation composition can have varying effects on the model prediction. In this case, Q residuals and Hotelling T 2 scores (Fig. 9) were evaluated which are statistical tests that can provide a quantitative assessment of anomalous samples (Li et al., 2010) . Both the Q residuals and T 2 scores were high and well exceeded the pre-determined 95% confidence levels, indicating that the test printlets were not similar to the calibration printlets and could hence be deemed as 'outliers'. Despite this, the model maintained a good predictive performance which is likely due to the majority of the data variation being attributed to the change in paracetamol concentration (LV1 = 88.8%) rather than the polymer. However, from a regulatory perspective and to ensure model accuracy in the clinic, it is likely that a calibration model that covers the expected excipient changes or, alternatively, a separate model for different printlet compositions would have to be devised.
Precision
The precision of the calibration model required evaluation to elucidate the degree of agreement between separate test results upon repeated sampling. In the present study, precision was evaluated by scanning a low dose printlet (6% w/w), in triplicate on each of the six points, at the same time of day whilst using the same equipment. Six different points were scanned and averaged for each tablet to reduce the potential spectral variability caused by differing surface effects. However, this number could be reduced further, for example, by using larger probes that could scan a bigger region of the tablet surface.
If a 3D printer were to be integrated into pharmacy practice, it is likely that printlets would be produced at different times of day and in different locations. As such, intermediate precision was also evaluated by performing the same test two weeks later, at a different time of day and in a different equipment location. Table 4 shows the results of precision and intermediate precision. For both tests, the standard deviation was low (0.06 and 0.23% w/w, respectively) and was below the RMSEP value of 0.63%, again demonstrating model accuracy. For precision and intermediate precision, the relative standard deviation (RSD) values were also low at < 5% (0.91% and 3.80%, respectively), demonstrating that the model displays good precision in different experimental conditions. Compared with HPLC, the use of NIR to measure drug concentration demonstrated a higher SD and RSD, which is not unexpected due to the known impact of surface effects on NIR spectra. However, as an alternative method to measure drug concentration in the clinic, the error demonstrated is low and would be unlikely to be of clinical significance.
Validation of the developed PLS model confirmed that the use of NIR spectroscopy could provide a feasible alternative to conventional, destructive dose verification methods (e.g. HPLC and UV spectroscopy). Favourably, the 'point-and-shoot' approach developed in the present study is highly user-friendly and provides a rapid dose prediction with each tablet scan lasting only ∼10 s. As such, it is likely that the developed model would be suitable for QC purposes in the clinic. Previous research has mainly focussed on demonstrating this concept for inkjet printed pharmaceuticals. For example, Vakili et al. developed a colourimetric quantification technique for oral films by adding a colourant to the drug-loaded ink which was scanned using a colourimeter (Vakili et al., 2016) . By increasing the number of layers printed, a greater intensity of colour was detected and, as such, the dose could be quantified. The same research group also demonstrated the feasibility of using of a handheld NIR spectrometer to predict levothyroxine and prednisolone content in inkjet printed oro-dispersible films (Vakili et al., 2017) . Trenfield et al. International Journal of Pharmaceutics 549 (2018) 283-292 The use of NIR chemical imaging (NIR-CI) as a quality control method for hot melt extruded filaments and printlets has also been evaluated (Khorasani et al., 2016) . The researchers used multivariate curve resolution-alternative least squares (MCR-ALS) to predict drug content. However, in that study a calibration model was not used and, as such, MCR-ALS could only be classed as a semi-quantitative method. For a full quantitative characterisation, the development of a calibration model using partial least squares (PLS) regression is widely used (Ravn et al., 2008; Roggo et al., 2007) with the FDA and EMA guidance recognising the use of PLS as a quantitative tool (EMA, 2014; FDA, 2015) . As such, it is likely that the developed model in the present study would be more suitable for QC purposes in the clinic.
Due to the development of small spectroscopic systems, in the future, these platforms could be integrated within a 3D printer. This advancement could overcome the regulatory challenges surrounding the integration of 3D printing in clinical practice by providing the ability to both personalise dosage forms and ensure QC within a single step process.
Conclusion
3DP is forecast to transition the manufacture of medicines away from a 'one-size-fits-all' approach towards personalisation. To facilitate integration of 3DP into clinical pharmacy practice, the evaluation of non-destructive dose verification and characterisation techniques are required to ensure final product quality. This article has demonstrated the feasibility of using process analytical technologies to measure paracetamol concentration (4-40% w/w) in printlets of different geometries, formulation types and excipients. The developed model was validated according to current international standards, demonstrating excellent linearity (R 2 = 0.996) and accuracy (RMSEP = 0.63%). This manuscript reports for the first time the development of a rapid, nondestructive quality control method for 3D printed dosage forms, providing a transformative approach to support the integration of 3DP into clinical pharmacy practice.
